A Study of LY4178256 in Healthy Participants
ConditionHealthy Volunteers
Trial statusNot yet recruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-65
SponsorEli Lilly and Company
About this trial
The main purpose of this study is to evaluate how well LY4178256 is tolerated and what side effects may occur in healthy participants. Blood tests will be performed to check how much LY4178256 gets into the bloodstream and how long it takes the body to eliminate it. For each participant, the study will last about 7 months and will include either 7 or 12 visits depending on the assigned treatment.
Eligibility criteria
Qualifiers
Are overtly healthy as determined by medical evaluation including medical history, physical examination, and other screening procedures.
Have a body mass index within the range of 19.0 to 32.0 kilograms per square meter (kg/m²)
Individuals assigned male at birth willing to practice effective contraception throughout the study and individuals assigned female at birth not of childbearing potential may participate in this trial.
Disqualifiers
Have significant history of or current cardiovascular, respiratory, renal, gastrointestinal, endocrine, hematological, dermatological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the Investigational Medicinal Product (IMP); or of interfering with the interpretation of data.
Have abnormal blood pressure
Have a 12-lead electrocardiogram (ECG) abnormality at screening that, in the opinion of the investigator, increases the risks associated with participating in the study, have a mean QT interval corrected using Fridericia's formula (QTcF) of greater than 450 milliseconds (>450 msec) for males, or >470 msec for females.
Regularly use known drugs of abuse or with positive drug results (within the past 3 months).
Trial design
Treatments tested in this trial
- LY4178256
- Placebo
Treatment groups
88 Participants
are divided into 2 treatment groupsLocations
2Collaborative Neuroscience Network - CNS90720, Los AlamitosCalifornia, United States
ICON84124, Salt Lake CityUtah, United States
Sponsors and collaborators
Eli Lilly and Company
Lead sponsor
Source ClinicalTrials.gov